These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27866006)

  • 21. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
    Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
    J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
    Shanshanwal SJ; Dhurat RS
    Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs.
    Pirozzi Farina F; Pischedda A
    Arch Ital Urol Androl; 2016 Jan; 87(4):312-6. PubMed ID: 26766804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Cardiovascular Safety of Five-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
    Ayele HT; Reynier P; Azoulay L; Platt RW; Benayoun S; Filion KB
    Am J Med; 2023 Oct; 136(10):1000-1010.e7. PubMed ID: 37481022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical post-finasteride syndrome: A pharmacological riddle.
    Gupta AK; Sharma N; Shukla P
    Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
    Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
    Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.
    Loke YK; Ho R; Smith M; Wong O; Sandhu M; Sage W; Singh S
    J Clin Pharm Ther; 2013 Oct; 38(5):405-15. PubMed ID: 23815285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
    Mačukat IR; Spanjol J; Orlič ZC; Butorac MZ; Marinovič M; Ćupič DF
    Coll Antropol; 2014 Sep; 38(3):835-9. PubMed ID: 25420363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.
    Lin WL; Hsieh YW; Lin CL; Sung FC; Wu CH; Kao CH
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):503-8. PubMed ID: 25158777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
    Arena F
    Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer.
    Duijnhoven RG; Straus SM; Souverein PC; de Boer A; Bosch JL; Hoes AW; De Bruin ML
    Cancer Causes Control; 2014 Nov; 25(11):1577-82. PubMed ID: 25135615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases.
    Yang DY; Seo WW; Park RW; Rhee SY; Cha JM; Hah YS; Jeong CW; Kim KJ; Yang HJ; Kim DK; Ha JY
    World J Mens Health; 2024 May; ():. PubMed ID: 38772542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
    Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 40. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
    Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
    JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.